Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

SML0289

Sigma-Aldrich

Bromfenac sodium

≥98% (HPLC)

Synonym(e):

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C15H11BrNNaO3
CAS-Nummer:
91714-93-1
Molekulargewicht:
356.15
MDL-Nummer:
MFCD03701673
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329825297
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

faintly yellow to dark yellow

Löslichkeit

H2O: ≥5 mg/mL

Lagertemp.

2-8°C

SMILES String

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

InChIKey

HZFGMQJYAFHESD-UHFFFAOYSA-M

Angaben zum Gen

human ... PTGS1(5742) , PTGS2(5743)

Anwendung

Bromfenac sodium has been used:
  • to study its ability to bind to melanin
  • in the synthesis of bromfenac indolinone standard
  • to analyze its permeability in porcine conjunctiva

Biochem./physiol. Wirkung

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.

Piktogramme

Skull and crossbones
GHS06

Signalwort

Danger

H-Sätze

H301

Gefahreneinstufungen

Acute Tox. 3 Oral

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
126M4755V
032M4744V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 1

1 of 1

Dexamethason powder, BioReagent, suitable for cell culture, ≥97%

Sigma-Aldrich

D4902

Dexamethason

Christina Flaxel et al.
Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)
To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were
Jeffrey S Heier et al.
Retina (Philadelphia, Pa.), 29(9), 1310-1313 (2009-11-26)
To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy. This was an investigator-masked, randomized, multicenter study. Patients received ketorolac 0.4% 4 times a day, bromfenac 0.09% 2 times a day
Frank A Bucci et al.
Advances in therapy, 28(12), 1089-1095 (2011-11-23)
We compared the prostaglandin E(2) (PGE(2)) inhibition of three topical nonsteroidal antiinflammatory drugs (NSAIDs): ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% at peak dosing levels in patients previously scheduled to undergo phacoemulsification. This was a single-center, double-masked observational study of
Frank A Bucci et al.
Current medical research and opinion, 27(12), 2235-2239 (2011-10-14)
To compare the peak to-aqueous penetration of three nonsteroidal anti-inflammatory drugs: ketorolac tromethamine 0.45%, bromfenac 0.09%, nepafenac 0.1%, and amfenac (the active metabolite of nepafenac) in patients undergoing phacoemulsification. A single center, double-masked study randomized 122 patients to receive one
Koichiro Mukai et al.
Journal of cataract and refractive surgery, 35(9), 1614-1618 (2009-08-18)
To evaluate the efficacy of ophthalmic nonsteroidal and steroidal antiinflammatory drugs in preventing anterior capsule contraction and secondary posterior capsule opacification (PCO) using an experimental cataract model. Department of Ophthalmology, Dokkyo Medical University, Tochigi, Japan. Eight-week-old albino rabbits weighing about
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.